Company Focus
Icon
Latest Icon News
Biotechnology
Irish contract research organization ICON has retained its position as the most active CRO worldwide in the first quarter of 2025, according to a new analysis by GlobalData. 16 May 2025
Related News
Insights
Company Spotlight
Microbiotica was launched in December 2016 with the aim of creating a global leader to exploit the leading microbiome science built at the Wellcome Trust Sanger Institute.
Latest News & Features of interest to Icon
Biotechnology
Spanish biotech SpliceBio has secured $135 million in series B financing to accelerate development of its experimental gene therapy, SB-007, for Stargardt disease and expand its broader pipeline of genetic medicines. 11 June 2025
Pharmaceutical
Last month, the Future Health Report was presented at the World Health Assembly in Geneva, Switzerland. 10 June 2025
Biotechnology
Oxford, UK-based biotech SynaptixBio, which is developing a therapy for a rare, deadly, and currently incurable rare disease (H-ABC), says it has identified the drug it will take forward into clinical trials. 10 June 2025
Biotechnology
UK privately-held T-regulatory (Treg) cell therapies developer Quell Therapeutics today revealed that pharma major AstraZeneca has selected a lead Treg cell therapy candidate to progress from the inflammatory bowel disease (IBD) program. 10 June 2025
Pharmaceutical
UK-based microbiome company Microbiotica has appointed Robert Tansley its chief medical officer (CMO). 10 June 2025
Pharmaceutical
New York-based Metsera, a biopharma developing medicines for obesity and metabolic diseases, closed Monday’s trading nearly 11% higher. 10 June 2025
Biotechnology
June 10, 2025
The US Food and Drug Administration (FDA) has approved Enflonsia (clesrovimab-cfor) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in neonates (newborns) and infants who are born during or entering their first RSV season, US pharma giant Merck & Co revealed yesterday. 10 June 2025
Biotechnology
Dutch late-stage biotech NewAmsterdam Pharma late yesterday announced positive top-line data from prespecified Alzheimer’s disease (AD) biomarker analyses in the Phase III BROADWAY clinical trial (NCT05142722). The firm’s US-traded shares were up 4.1% at $20.99 in pre-market activity this morning. 10 June 2025
Biotechnology
Shares of USA-based Elevation Oncology leapt more than 20% to $0.38, on the news that it has accepted a takeover bid from Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners, an investment firm focused on buying struggling biotechs and shutting them down. 10 June 2025
Pharmaceutical
US Health Secretary Robert F. Kennedy Jr has removed all 17 members of a key vaccine advisory committee, a move officials say is aimed at rebuilding public trust in the country’s immunization policies. 10 June 2025
Latest In Brief for Icon
Pharmaceutical
Shares of Swedish drugmaker Camurus shot up 23% to 638.50 kronor yesterday on news of that it has entered a collaboration and license agreement with Eli Lilly, granting the US pharma major exclusive, worldwide rights to the research, development, manufacture, and commercialization of long-acting incretin products for cardiometabolic health based on Camurus’ FluidCrystal technology. 6 June 2025
Latest Relevant Ones To Watch News
Shares of USA-based Elevation Oncology leapt more than 20% to $0.38, on the news that it has accepted a takeover bid from Concentra Biosciences, a vehicle controlled by hedge fund Tang Capital Partners, an investment firm focused on buying struggling biotechs and shutting them down. 10 June 2025
28 May 2025
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze